Users Online: 771

Home Print this page Email this page Small font sizeDefault font sizeIncrease font size

Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Login 
Year : 2011  |  Volume : 1  |  Issue : 2  |  Page : 116-125

Effect of metformin combined therapy in patients with polycystic ovary syndrome

1 Department of Biochemistry & Biotechnology, Bharathiyar University, Coimbatore, India
2 Department of Biochemistry, Government Arts and Science College for women, Krishnagiri, India
3 Clinical Biochemistry, K. G. Hospital and Post graduate Medical Institute, Coimbatore, Tamil Nadu, India

Correspondence Address:
Dhanalakshmi Ganesan
Research scholar, Bharathiyar university, Coimbatore, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2231-0738.84201

Rights and Permissions

Polycystic ovary syndrome (PCOS) is a common and heterogeneous disorder of women of reproductive age, characterized by hyperandrogenism and chronic anovulation. Metformin may lower the androgen level in follicular fluid, affecting local levels of IGF (Insulin like growth factor)s, and may produce improved ovarian stimulation. Metformin is used in PCOS cases in order to decrease plasma luteinizing hormone (LH), hyperinsulinemia, and ovarian androgen levels. Metformin increases the ovulatory rate, cervical scores and pregnancy rate. This review article focuses on the combined effect of metformin administration in PCOS patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded403    
    Comments [Add]    

Recommend this journal